CA-ANDERSEN-GLOBAL
29.9.2023 17:25:34 CEST | Business Wire | Pressemeddelelse
Andersen, det hurtigst voksende uafhængige, tværfaglige professionelle servicefirma i verden, har lanceret en ny global værdiansættelsespraksis. Ønsket er at udvide kundeplatformen med skattemæssige, juridiske og beslægtede services. Andersens globale værdiansættelsesteam arbejder med virksomheder, fonde, enkeltpersoner med stor indre værdi og familiekontorer om udførelse af værdiansættelser af virksomheder, materielle og immaterielle aktiver og komplekse værdipapirer med henblik på indberetning af skat, rapportering af finansielle oplysninger og rådgivning i transaktionsspørgsmål. Kundegrundlaget er en bred vifte af brancher inden for alt fra teknologi til fremstilling og fra landbrug til biomedicin.
På lanceringstidspunktet eksisterer Andersens globale værdiansættelsespraksis i mere end 20 lande verden over på tværs af Nordamerika, Europa, Latinamerika, Mellemøsten og Asien.
"Skat, jura og værdiansættelse er tæt forbundne, men ingen anden professionel servicevirksomhed tilbyder alle disse faciliteter på globalt plan under samme tag," udtaler Andersen Global Chairman og CEO Mark Vorsatz. "Hos Andersen har vi en vision om at skabe en platform, hvor kunderne får en problemfri oplevelse af én tværfaglig virksomhed, de kan stole på, hvor som helst i verden. Vores mål er at blive et af de største uafhængige værdiansættelsesfirmaer i verden inden for de næste få år."
I spidsen for Andersens nye globale værdiansættelsespraksis står Managing Director Sid Luckenbach, som på nationalt plan i USA har stået for firmaets udbud af værdiansættelse i de seneste 18 år.
"Forretningsstrukturer og finansielle instrumenter bliver mere komplekse," siger Luckenbach. "Kompleksiteten stiger, når man har at gøre med grænseoverskridende transaktioner på tværs af flere retsområder. Derfor er den traditionelle tilgang ikke længere tilstrækkelig. Vores globale værdiansættelsespraksis samler den bundsolide ekspertise og geografiske rækkevidde, som kunderne efterspørger, uanset hvor deres aktiver er placeret."
Andersen Global er en international sammenslutning af juridisk adskilte og uafhængige medlemsvirksomheder, der består af skatteeksperter og -jurister i hele verden. Andersen Global, der blev etableret i 2013 af den amerikanske medlemsvirksomhed Andersen Tax LLC, har nu mere end 14.000 eksperter i hele verden og en tilstedeværelse på over 400 lokaliteter gennem sine medlemsvirksomheder og samarbejdsvirksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20230927729165/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
